Search Result

Isoforms Recommended:	HDAC3

Results for "

HDAC3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (34) Autophagy (5) Bcl-2 Family (1) Caspase (2) CDK (3) DNA/RNA Synthesis (1) Filovirus (2) FLT3 (2) Guanylate Cyclase (1) HDAC (84) Histone Methyltransferase (1) HIV (1) HPV (2) iGluR (1) JAK (1) Microtubule/Tubulin (1) Mitophagy (2) Parasite (2) PARP (1) PI3K (2) PROTACs (1) Proteasome (1) Reactive Oxygen Species (1) Small Interfering RNA (siRNA) (3) Topoisomerase (2)
By Research Areas:	Cancer (76) Infection (7) Inflammation/Immunology (3) Neurological Disease (5)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-RS06070

HDAC3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HDAC3 Human Pre-designed siRNA Set A contains three designed siRNAs for HDAC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HDAC3 Human Pre-designed siRNA Set A HDAC3 Human Pre-designed siRNA Set A

HY-RS06071

Hdac3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Hdac3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hdac3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hdac3 Mouse Pre-designed siRNA Set A Hdac3 Mouse Pre-designed siRNA Set A

HY-RS06072

Hdac3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Hdac3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Hdac3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Hdac3 Rat Pre-designed siRNA Set A Hdac3 Rat Pre-designed siRNA Set A

HY-161154

HDAC3-IN-3

HDAC Cancer

HDAC3-IN-3 (compound 31) is a potent HDAC3 inhibitor. HDAC3-IN-3 has the potential for the research of cancer .
HY-117374

HDAC3-IN-1

HDAC Cancer

HDAC3-IN-1 (compound 5) is a potent and selective HDAC3 inhibitor, with an IC₅₀ of 5.96 nM .

HDAC3-IN-3	HDAC	Cancer
HDAC3-IN-3 (compound 31) is a potent *HDAC3* inhibitor. HDAC3-IN-3 has the potential for the research of cancer .

HDAC3-IN-1	HDAC	Cancer
HDAC3-IN-1 (compound 5) is a potent and selective *HDAC3* inhibitor, with an IC₅₀ of 5.96 nM .

HY-123295

HDAC3-IN-T247	HDAC	Infection Cancer
HDAC3-IN-T247 is a potent and selective *HDAC3* (histone deacetylase 3) inhibitor, with an IC₅₀ of 0.24 µM. HDAC3-IN-T247 induces a selective increase of NF-κB acetylation in HCT116 cells. HDAC3-IN-T247 shows anticancer and antiviral activity. HDAC3-IN-T247 inhibits growth of cancer cells, and activates HIV gene expression in latent HIV-infected cells .

HY-133147

HDAC3/6-IN-2	HDAC Apoptosis	Cancer
HDAC3/6-IN-2 (compound 15) is a potent *HDAC6* and *HDAC3* inhibitor, with IC₅₀ values of 0.368 and 0.635 μM, respectively. HDAC3/6-IN-2 shows antitumor activity, and induces cancer cell apoptosis. HDAC3/6-IN-2 decreases the levels of *HDAC6* and *HDAC3*, associated with upregulation of acetylated H3 and α-tubulin .

HY-156096

HDAC3-IN-2	HDAC Histone Methyltransferase Caspase Apoptosis DNA/RNA Synthesis	Cancer
HDAC3-IN-2 (compound 4i) is a pyrazinyl hydrazide-based HDAC3 inhibitor (IC₅₀: 14 nM) that efficiently targets triple-negative breast cancer cells. HDAC3-IN-2 is cytotoxic with an IC₅₀ of 0.55 μM against 4T1 and an IC₅₀ of 0.74 μM against MDA-MB-231. HDAC3-IN-2 has anti-tumor efficacy in vivo in tumor-bearing mouse models, selectively increasing the acetylation levels of H3K9, H3K27 and H4K12, increasing the contents of apoptosis-related caspase-3, caspase-7 and cytochrome c, and reducing Proliferation-related Bcl-2, CD44, EGFR, and Ki-67 levels .

HY-16425

RG2833 5 Publications Verification RGFP109	HDAC	Cancer
RG2833 is a brain-penetrant *HDAC* inhibitor with IC₅₀s of 60 nM and 50 nM for HDAC1 and HDAC3, respectively. The K_i values for HDAC1 and HDAC3 are 32 and 5 nM, respectively .

HY-114483

AES-135 1 Publications Verification	HDAC	Cancer
AES-135, a hydroxamic acid-based pan-HDAC inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer. AES-135 inhibits HDAC3, HDAC6, HDAC8, and HDAC11 with IC₅₀s ranging from 190-1100 nM .

HY-119017

SB-429201

HDAC Cancer

SB-429201 is a potent and selective HDAC1 (IC₅₀~1.5 μM). SB-429201 displays at least a 20-fold preference for HDAC1 inhibition over HDAC3 and HDAC8 .

SB-429201	HDAC	Cancer
SB-429201 is a potent and selective *HDAC1* (IC₅₀~1.5 μM). SB-429201 displays at least a 20-fold preference for HDAC1 inhibition over HDAC3 and HDAC8 .

HY-100748

Zabadinostat 1 Publications Verification CXD101	HDAC	Cancer
Zabadinostat (CXD101) is a potent, selective and orally active class I *HDAC* inhibitor with IC₅₀s of 63 nM, 570 nM and 550 nM for *HDAC1, HDAC2* and *HDAC3, respectively. Zabadinostat has no activity against HDAC* class II. Zabadinostat has antitumor activity .

HY-110264

MI-192	HDAC Apoptosis	Neurological Disease Cancer
MI-192 is a selective *HDAC2* and *HDAC3* inhibitor with IC₅₀s of 30 nM and 16 nM, respectively. MI-192 is more selective for HDAC2/3 than other HDAC isomers.MI-192 induces myeloid leukaemic cells apoptosis. Anticaner and neuroprotective activities .

HY-18712

BG45 2 Publications Verification	HDAC Apoptosis Caspase	Cancer
BG45 is a potent *HDAC3* inhibitor with IC₅₀ values of 0.289, 2, 2.2 and ﹥20 μM for HDAC3, HDAC1, HDAC2 and HDAC6, respectively. BG45 selectively targets multiple myeloma (MM) cells and induces caspase-dependent apoptosis .

HY-13267

Droxinostat 2 Publications Verification NS 41080	HDAC Apoptosis	Cancer
Droxinostat (NS 41080) is a histone deacetylase (HDAC) inhibitor. Droxinostat selectively inhibits HDAC3, HDAC6, and HDAC8 with IC₅₀ values of 16.9 μM, 2.47 μM, and 1.46 μM, respectively. Droxinostat can be used for the research of hepatocellular carcinoma (HCC) .

HY-14842B

Givinostat hydrochloride monohydrate 5+ Cited Publications ITF-2357 hydrochloride monohydrate	HDAC	Cancer
Givinostat hydrochloride monohydrate (ITF-2357 hydrochloride monohydrate) is a *HDAC* inhibitor with an IC₅₀ of 198 and 157 nM for *HDAC1* and *HDAC3*, respectively.

HY-14842

Givinostat

5+ Cited Publications

ITF-2357
HDAC Cancer

Givinostat (ITF-2357) is a HDAC inhibitor with an IC₅₀ of 198 and 157 nM for HDAC1 and HDAC3, respectively.

Givinostat 5+ Cited Publications ITF-2357	HDAC	Cancer
Givinostat (ITF-2357) is a *HDAC* inhibitor with an IC₅₀ of 198 and 157 nM for *HDAC1* and *HDAC3*, respectively.

HY-14842A

Givinostat hydrochloride ITF-2357 hydrochloride	HDAC	Cancer
Givinostat (ITF-2357) hydrochloride is a *HDAC* inhibitor with an IC₅₀ of 198 and 157 nM for *HDAC1* and *HDAC3*, respectively ^[3].

HY-W019710

(E,E)-RGFP966

HDAC Neurological Disease

(E,E)-RGFP966 is a selective and CNS permeable HDAC3 inhibitor that can be used for the research of Huntington’s disease .

(E,E)-RGFP966	HDAC	Neurological Disease
(E,E)-RGFP966 is a selective and CNS permeable *HDAC3* inhibitor that can be used for the research of Huntington’s disease .

HY-157740

XSJ-10	HDAC	Cancer
XSJ-10 is a *HDAC* inhibitor containing a RAS/RAF protein interfering unit, with IC_{50_s} of 0.05 and 0.04 μM in PANC-1 cells and HT-29 cells. XSJ-10 can effectively induce the apoptosis of cancer cells and suppress the tumor by strongly inhibiting the RAS-RAF-MEK-ERK signaling pathway and the acetylation level of HDAC3 .

HY-10221

Vorinostat Maximum Cited Publications 87 Publications Verification SAHA; Suberoylanilide hydroxamic acid	HDAC Autophagy Mitophagy Filovirus Apoptosis HPV	Infection Cancer
Vorinostat (SAHA) is a potent and orally active pan-inhibitor of *HDAC1, HDAC2* and HDAC3 (Class I), *HDAC6* and HDAC7 (Class II) and HDAC11 (Class IV), with ID₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis . Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification .

HY-12163

Entinostat 35+ Cited Publications MS-275; SNDX-275	HDAC Autophagy Apoptosis	Cancer
Entinostat is an oral and selective class I *HDAC* inhibitor, with IC₅₀s of 243 nM, 453 nM, and 248 nM for *HDAC1, HDAC2, and HDAC3*, respectively.

HY-119690

T326

HDAC HIV Infection Cancer

T326 is a potent and selective HDAC3 inhibitor, with an IC₅₀ of 0.26 μM. T326 can be used for the research of cancer and HIV infection .

T326	HDAC HIV	Infection Cancer
T326 is a potent and selective *HDAC3* inhibitor, with an IC₅₀ of 0.26 μM. T326 can be used for the research of cancer and HIV infection .

HY-152225

MC2625	HDAC Apoptosis	Cancer
MC2625 is a potent pyridine-containing histone deacetylase (HDAC) inhibitor. MC2625 show selective HDAC3 and HDAC6 inhibition with IC₅₀s of 80 nM and 11 nM. MC2625 increases acetyl-H3 and acetyl-tubulin levels and inhibits cancer stem cells (CSCs) growth by apoptosis induction .

HY-115412

Vorinostat-d5 SAHA-d5; Suberoylanilide hydroxamic acid-d5	HDAC Autophagy Mitophagy Filovirus Apoptosis HPV	Infection Cancer
Vorinostat-d5 (SAHA-d5) is the deuterium labeled Vorinostat. Vorinostat (SAHA) is a potent and orally active pan-inhibitor of *HDAC1, HDAC2* and HDAC3 (Class I), HDAC7 (Class II) and HDAC11 (Class IV), with ID₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis . Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification .

HY-19618

BRD3308
BRD3308 is a highly selective *HDAC3* inhibitor with an IC₅₀ of 54 nM. BRD3308 is 23-fold selectivity for *HDAC3* over HDAC1 (IC₅₀ of 1.26 μM) or HDAC2 (IC₅₀ of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency ^[3].

HY-13909

RGFP966 25+ Cited Publications	HDAC	Cancer
RGFP966 is a highly selective *HDAC3* inhibitor with an IC₅₀ of 80 nM and shows no inhibition to other HDACs at concentrations up to 15 μM. RGFP966 can penetrate the blood brain barrier (BBB).

HY-101780

Tinostamustine 3 Publications Verification EDO-S101; NL-101	HDAC	Cancer
Tinostamustine (EDO-S101) is a pan *HDAC* inhibitor; inhibits *HDAC6, HDAC1, HDAC2* and *HDAC3* with IC₅₀ values of 6 nM, 9 nM, 9 nM and 25 nM, respectively .

HY-N6017

Bakkenolide A	HDAC	Cancer
Bakkenolide A is a natural product extracted from Petasites tricholobus. Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways .

HY-146346

HD-TAC7	PROTACs HDAC	Inflammation/Immunology
HD-TAC7 is a potent PROTAC HDAC degrader with IC₅₀ values of 3.6 μM, 4.2 μM and 1.1 μM for HDAC1, HDAC2 and HDAC3, respectively. HD-TAC7 can decreases NF-κB p65 in RAW 264.7 macrophages. HD-TAC7 can be used for the research of inflammatory diseases like asthma and chronic obstructive pulmonary disease (COPD) .

HY-153583

HDAC8-IN-4

HDAC Cancer

HDAC8-IN-4 is a selective inhibitor of HDAC8. HDAC8-IN-4 inhibits HDAC8 and HDAC3 with IC₅₀s of 0.15 and 12 μM .

HDAC8-IN-4	HDAC	Cancer
HDAC8-IN-4 is a selective inhibitor of *HDAC8. HDAC8-IN-4 inhibits HDAC8 and HDAC3* with IC₅₀s of 0.15 and 12 μM .

HY-19754A

CRA-026440 hydrochloride	HDAC Apoptosis	Cancer
CRA-026440 hydrochloride is a potent, broad-spectrum *HDAC* (HDAC) inhibitor. The K_i values against recombinant HDAC isoenzymes *HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10* are 4 nM, 14 nM, 11 nM, 15 nM, 7 nM, and 20 nM respectively. CRA-026440 hydrochloride shows antitumor and antiangiogenic activities . CRA-026440 (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14718A

Resminostat hydrochloride 2 Publications Verification RAS2410 hydrochloride; 4SC-201 hydrochloride	HDAC	Cancer
Resminostat hydrochloride is a potent inhibitor of *HDAC1, HDAC3* and *HDAC6, with mean IC₅₀* values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC₅₀ of 877 nM.

HY-16026

Ricolinostat 20+ Cited Publications ACY-1215; Rocilinostat	HDAC Apoptosis	Cancer
Ricolinostat (ACY-1215) is a potent and selective *HDAC6* inhibitor, with an IC₅₀ of 5 nM. ACY-1215 also inhibits *HDAC1, HDAC2, and HDAC3* with IC₅₀s of 58, 48, and 51 nM, respectively.

HY-W014004

m-Carboxycinnamic acid bishydroxamide CBHA	HDAC	Cancer
m-Carboxycinnamic acid bishydroxamide is a potent *HDAC* inhibitor, exhibiting ID₅₀ values of 10 and 70 nM in vitro for HDAC1 and HDAC3, respectively . m-Carboxycinnamic acid bishydroxamide also induces apoptosis and suppresses tumor growth .

HY-151896

HDAC6-IN-14

HDAC Cancer

HDAC6-IN-14 is a highly selective HDAC6 (HDAC) inhibitor with an IC₅₀ of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4 .

HDAC6-IN-14	HDAC	Cancer
HDAC6-IN-14 is a highly selective *HDAC6* (HDAC) inhibitor with an IC₅₀ of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4 .

HY-19327

ACY-738 2 Publications Verification	HDAC	Cancer
ACY-738 is a potent, selective and orally-bioavailable *HDAC6* inhibitor, with an IC₅₀ of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with IC₅₀s of 94, 128, and 218 nM.

HY-112908

RTS-V5

HDAC Proteasome Cancer

RTS-V5 is a dual HDAC/proteasome inhibitor with IC₅₀s of 6.9, 18, 15, 0.27, 0.53 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively.

RTS-V5	HDAC Proteasome	Cancer
RTS-V5 is a dual *HDAC/proteasome* inhibitor with IC₅₀s of 6.9, 18, 15, 0.27, 0.53 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively.

HY-12163S

Entinostat-d4 MS-275-d₄; SNDX-275-d₄	Apoptosis Autophagy HDAC	Cancer
Entinostat-d₄ is the deuterium labeled Entinostat[1]. Entinostat is an oral and selective class I HDAC inhibitor, with IC50s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively[2].

HY-N0071

Crotonoside Isoguanosine	FLT3 HDAC	Cancer
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits *FLT3* and *HDAC3/6*, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML .

HY-111400

SR-4370

HDAC Cancer

SR-4370 is an inhibitor of HDAC, with IC₅₀s of 0.13 μM, 0.58 μM, 0.006 μM, 2.3 μM, and 3.4 μM for HDAC1, HDAC2, HDAC3, HDAC8, and HDAC6, respectively.

SR-4370	HDAC	Cancer
SR-4370 is an inhibitor of *HDAC, with IC₅₀s of 0.13 μM, 0.58 μM, 0.006 μM, 2.3 μM, and 3.4 μM for HDAC1, HDAC2, HDAC3, HDAC8, and HDAC*6, respectively.

HY-14718

Resminostat RAS2410; 4SC-201	HDAC	Cancer
Resminostat (RAS2410; 4SC-201) is a potent inhibitor of *HDAC1, HDAC3* and *HDAC6, with mean IC₅₀* values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC₅₀ of 877 nM.

HY-147731

HDAC6-IN-9	HDAC	Cancer
HDAC6-IN-9 (compound 12c) is a potent and selective *HDAC6* inhibitor with IC₅₀ values of 11.8, 15.2, 4.2, 139.6, 21.3 nM for HDAC1,HDAC3, HDAC6, HDAC8, HDAC10, respectively. HDAC6-IN-9 shows anti-proliferative activities .

HY-152174

HDAC-IN-52	HDAC	Cancer
HDAC-IN-52 is a pyridine-containing *HDAC* inhibitor, with IC₅₀s of 0.189, 0.227, 0.440 and 0.446 μM for *HDAC1, HDAC2, HDAC3, and HDAC10, respectively. HDAC*-IN-52 can be used for the research of cancer .

HY-149283

*JAK/HDAC-IN-2*	JAK HDAC Apoptosis	Cancer
JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine *JAK/HDAC* dual-target inhibitor. JAK/HDAC-IN-2 potently inhibits HDAC3/6 and JAK1/2 at nanomolar levels. JAK/HDAC-IN-2 has proapoptotic activity and inhibits histone deacetylation and STAT3 phosphorylation. JAK/HDAC-IN-2 presents remarkable antiproliferative activity in both hematological malignancies and solid cancers .

HY-15994

Citarinostat 3 Publications Verification ACY241	HDAC	Cancer
Citarinostat (ACY241) is a second generation potent, orally active and high-selective *HDAC6* inhibitor with an IC₅₀ of 2.6 nM (IC₅₀s of 35 nM, 45 nM, 46 nM and 137 nM for HDAC1, HDAC2, HDAC3 and HDAC8, respectively). Citarinostat has anticancer effects .

HY-147840

HDAC-IN-41	HDAC	Cancer
HDAC-IN-41 (Compound 7c) is a selective, orally active class I *HDAC* inhibitor with IC₅₀ values of 0.62, 1.46 and 0.62 μM against HDAC1, HDAC2 and HDAC3, respectively. HDAC-IN-41 shows NO releasing activity .

HY-155840

KH16	HDAC Apoptosis	Cancer
KH16 is a potent and low nanomolar HDAC inhibitor. KH16 is against class I HDACs HDAC1, HDAC2, and HDAC3, with IC₅₀ ?values ranging from 6 to 34 nM. KH16 induces cell apoptosis and is against tumor cells with various gene expression patterns .

HY-162086

HDAC-IN-68	HDAC	Cancer
HDAC-IN-68 (Compound 29) is a potent HDAC inhibitor that disrupts microtubule structure and inhibits tumor growth. HDAC-IN-68 significantly inhibits class I HDACs (HDAC1, HDAC2, HDAC3) with IC₅₀ values of 5.1, 11.5 and 8.8 nM, respectively .

HY-161050

YSR734	HDAC Apoptosis	Cancer
YSR734 (Compound 21) is a covalent *HDAC* inhibitor with IC₅₀ values of 110 nM, 154 nM, and 143 nM for *HDAC1, HDAC2, and HDAC3, respectively. YSR734 can induce apoptosis* in leukemia cells. YSR734 can induce myoblast differentiation and is used in the study of Duchenne muscular dystrophy .

Cat. No.	Product Name	Category	Target	Chemical Structure